Epigallocatechin gallate inhibits the HIV reverse transcription step - PubMed (original) (raw)

. 2011 Jul 4;21(6):239-43.

doi: 10.3851/IMP1774.

Affiliations

• PMID: 21730371
• DOI: 10.3851/IMP1774

Free article

Epigallocatechin gallate inhibits the HIV reverse transcription step

Shenwei Li et al. Antivir Chem Chemother. 2011.

Free article

Abstract

Background: Epigallocatechin gallate (EGCG), the most abundant catechin in green tea, has been reported to inhibit HIV-1 replication prior to its integration into host DNA via various proposed mechanisms; however, the specific main target(s) of EGCG remain unclear. In this study, we investigated a number of these proposed detailed mechanism(s) using a cell-based model.

Methods: Multinuclear activation of galactosidase indicator assays were used for all experiments, including examination of the time of addition and the synergisms with a nucleoside reverse transcriptase inhibitor, 3'-azido-3'-deoxythymidine (AZT).

Results: The experiments revealed that EGCG suppressed both HIV-1(IIIB) and HIV-2(EHO) infection in HeLa-CD4-LTR-β-gal cells, with relatively low 50% effective concentrations of 1.6 and 2.0 μM, respectively. The inhibitory profile of EGCG generated using a time-of-addition assay was identical to that of a non-nucleoside reverse transcriptase inhibitor (NNRTI), MKC-442. Furthermore, synergistic inhibition was observed in EGCG with AZT.

Conclusions: Based on our findings, EGCG appears to act mainly as an allosteric reverse transcriptase inhibitor with mechanisms different from those of currently approved NNRTIs that directly interact with the NNRTI binding pocket. Thus, EGCG is a good candidate for use as an additional or supportive anti-HIV agent derived from natural plants.

PubMed Disclaimer

Similar articles

• Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442.
  Yuasa S, Sadakata Y, Takashima H, Sekiya K, Inouye N, Ubasawa M, Baba M. Yuasa S, et al. Mol Pharmacol. 1993 Oct;44(4):895-900. Mol Pharmacol. 1993. PMID: 7694070
• Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro.
  Baba M, Shigeta S, Yuasa S, Takashima H, Sekiya K, Ubasawa M, Tanaka H, Miyasaka T, Walker RT, De Clercq E. Baba M, et al. Antimicrob Agents Chemother. 1994 Apr;38(4):688-92. doi: 10.1128/AAC.38.4.688. Antimicrob Agents Chemother. 1994. PMID: 7518216 Free PMC article.
• Development of a pseudovirus assay and evaluation to screen natural products for inhibition of HIV-1 subtype C reverse transcriptase.
  Mavhandu LG, Cheng H, Bor YC, Tebit DM, Hammarskjold ML, Rekosh D, Bessong PO. Mavhandu LG, et al. J Ethnopharmacol. 2020 Aug 10;258:112931. doi: 10.1016/j.jep.2020.112931. Epub 2020 Apr 30. J Ethnopharmacol. 2020. PMID: 32360797
• Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors.
  Sluis-Cremer N, Tachedjian G. Sluis-Cremer N, et al. Virus Res. 2008 Jun;134(1-2):147-56. doi: 10.1016/j.virusres.2008.01.002. Epub 2008 Mar 26. Virus Res. 2008. PMID: 18372072 Free PMC article. Review.
• Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.
  Boone LR. Boone LR. Curr Opin Investig Drugs. 2006 Feb;7(2):128-35. Curr Opin Investig Drugs. 2006. PMID: 16499282 Review.

Cited by

• The green tea catechin EGCG provides proof-of-concept for a pan-coronavirus attachment inhibitor.
  LeBlanc EV, Colpitts CC. LeBlanc EV, et al. Sci Rep. 2022 Jul 28;12(1):12899. doi: 10.1038/s41598-022-17088-0. Sci Rep. 2022. PMID: 35902713 Free PMC article.
• First study on in vitro antiviral and virucidal effects of flavonoids against feline infectious peritonitis virus at the early stage of infection.
  Triratapiban C, Lueangaramkul V, Phecharat N, Pantanam A, Lekcharoensuk P, Theerawatanasirikul S. Triratapiban C, et al. Vet World. 2023 Mar;16(3):618-630. doi: 10.14202/vetworld.2023.618-630. Epub 2023 Mar 26. Vet World. 2023. PMID: 37041840 Free PMC article.
• ERK1/2-HNF4α axis is involved in epigallocatechin-3-gallate inhibition of HBV replication.
  Wang ZY, Li YQ, Guo ZW, Zhou XH, Lu MD, Xue TC, Gao B. Wang ZY, et al. Acta Pharmacol Sin. 2020 Feb;41(2):278-285. doi: 10.1038/s41401-019-0302-0. Epub 2019 Sep 25. Acta Pharmacol Sin. 2020. PMID: 31554961 Free PMC article.
• Epigallocatechin Gallate Inhibits Macaque SEVI-Mediated Enhancement of SIV or SHIV Infection.
  Zhou RH, Guo L, Liu JB, Liu H, Hou W, Ma TC, Wang X, Wu JG, Ye L, Ho WZ, Li JL. Zhou RH, et al. J Acquir Immune Defic Syndr. 2017 Jun 1;75(2):232-240. doi: 10.1097/QAI.0000000000001361. J Acquir Immune Defic Syndr. 2017. PMID: 28328549 Free PMC article.
• Nanotechnology Applications of Flavonoids for Viral Diseases.
  Jannat K, Paul AK, Bondhon TA, Hasan A, Nawaz M, Jahan R, Mahboob T, Nissapatorn V, Wilairatana P, Pereira ML, Rahmatullah M. Jannat K, et al. Pharmaceutics. 2021 Nov 8;13(11):1895. doi: 10.3390/pharmaceutics13111895. Pharmaceutics. 2021. PMID: 34834309 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program